Authors
Latest:
Dr. Padda on Selecting a Therapy Following Osimertinib Resistance in NSCLCSukhmani K. Padda, MD, discusses treatment selection following osimertinib resistance in patients with non–small cell lung cancer.
Latest:
Dr. Nagendran on Family History, BRCA Status, and RiskSukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, discusses a study looking at patients' family history, BRCA mutation status, and breast cancer risk.
Latest:
Dr. Kambhampati on Interferon and Novel Agents in MPNsSuman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Research Institute, HCA Midwest Health, discusses the role of interferon and emerging novel agents in the treatment of patients with myeloproliferative neoplasms.
Latest:
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual MeetingExperts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.
Latest:
Series Wrap-up: Novel Therapies for mRCCA panel of expert oncologists who manage patients with renal cell carcinoma share enthusiasm over the use of newer novel-based treatment approaches for metastatic disease.
Latest:
Sentinel Lymph Node Excision Has Value in Endometrial CancerAlthough the therapeutic utility of lymphadenectomy is uncertain, it continues to provide information for staging and helps to guide postoperative adjuvant treatment for patients with endometrial cancer.
Latest:
CAR T-Cell Therapy in Metastatic CRPC and Future Directions in CareClosing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.
Latest:
Dr. Jagannath on the Safety Profile of Selinexor in Multiple MyelomaSundar Jagannath, MD, discusses the use and toxicity profile of selinexor in multiple myeloma treatment.
Latest:
Dr. Sung Choi on Vorinostat in GVHD PreventionSung W. Choi, MD, Assistant Professor, University of Michigan, discusses the results of a phase I/II trial examining the use of the histone deacetylase (HDAC) inhibitor vorinostat in graft-versus-host disease (GVHD) prevention.
Latest:
Dr. Verma Discusses Biosimilars for TrastuzumabSunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses the potential role for trastuzumab (Herceptin) biosimilars.
Latest:
Dr. Verma Discusses Clinical Trial Endpoints in Metastatic Breast CancerSunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses targeting HER2 in early-stage breast cancer.
Latest:
Dr. Mohile On Prostate Cancer in Elderly PatientsDr. Supriya Mohile from the University of Rochester Medical Center Discusses Prostate Cancer in Elderly Patients
Latest:
Dr. Mohile on Implementing Geriatric Assessment into Cancer CareSupriya Gupta Mohile, MD, MS, professor of medicine and surgery, James Wilmot Cancer Institute, director, Geriatric Oncology Clinic, University of Rochester, discusses implementing geriatric assessments into cancer care.
Latest:
Ibrutinib Could Enhance CAR T-Cell Treatment Impact in CLLTreatment with concurrent ibrutinib improves expansion of chimeric antigen receptor T-cells and could subsequently improve response in patients with chronic lymphocytic leukemia, according to a study presented during the 2017 ASH Annual Meeting.
Latest:
Trial Backs 50-Gene Test in Neoadjuvant SettingNeoadjuvant chemotherapy for women diagnosed with breast cancer can help shrink a tumor prior to surgery, which can make the procedure minimally invasive and potentially influence prognosis.
Latest:
Dr. Shastri on Vinegar as a Cervical Cancer Screening ToolSurendra Srinivas Shastri, MD, Professor, Preventive Oncology, Tata Memorial Hospital, Mumbai, India, discusses the results of a study looking at vinegar (acetic acid) as a cervical cancer screening tool.
Latest:
Dr. Ramalingam on the Results of an Exploratory Analysis of the CheckMate 227 Trial in NSCLCSuresh S. Ramalingam, MD, FACP, FASCO, discusses the results of an exploratory analysis of the ongoing phase 3 CheckMate 227 trial in advanced non–small cell lung cancer.
Latest:
Dr. Ramalingam on Investigating Osimertinib Combination Approaches in NSCLCSuresh S. Ramalingam, MD, FACP, FASCO, discusses ongoing trials investigating osimertinib combination approaches in non-small cell lung cancer.
Latest:
Dr. Ramalingam on the Clinical Examination of Patritumab Deruxtecan in NSCLCSuresh S. Ramalingam, MD, FACP, FASCO, discusses the exploration of patritumab deruxtecan in non–small cell lung cancer.
Latest:
Dr. Ramalingam on the Potential of HER2 as a Driver Mutation in NSCLCSuresh S. Ramalingam, MD, FASCO, discusses the potential of HER2 as a driver mutation in non–small cell lung cancer.
Latest:
Dr. Ramalingam on the Efficacy of Trastuzumab Deruxtecan in HER2+ NSCLCSuresh S. Ramalingam, MD, FASCO, discusses the efficacy of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive non–small cell lung cancer.
Latest:
Unveiling the Plenary and Gynecologic Cancer Abstracts: Drs Ramalingam and O'MalleyOncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Latest:
Dr Ramalingam on Osimertinib Post-Chemoradiotherapy in Unresectable, Stage III, EGFR-Mutated NSCLCSuresh S. Ramalingam, MD, FACP, FASCO, discusses findings with osimertinib after definitive chemoradiotherapy in unresectable EGFR-mutated NSCLC.
